Ultrasound and Near Infrared Imaging for Breast Cancer Diagnosis and Neoadjuvant Chemotherapy Monitoring

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Breast Cancer
Interventions
OTHER

NIR/US Diagnostic Group

Patients receiving an ultrasound-guided biopsy will participate in one study visit on the day of the biopsy. The NIR/US scan will be completed immediately prior to the biopsy procedure and takes about 5-10 minutes to perform.

OTHER

NIR/US Neoadjuvant Chemotherapy Group

Patients may have the NIR/US scan performed at the time of their initial ultrasound-guided biopsy. In addition, patients in this group may also have NIR/US performed according the schedule in Table 1. The number of NIR/US study visits for these subjects will vary from 1-11 depending on the subject's treatment regimen. The expected duration of study participation for these patients is approximately 6 months.

OTHER

NIR/US Process Validation Group

Patients who present with visible lumps at initial ultrasound but do not have ultrasound visible lumps on the day of the biopsy procedure will not require a biopsy. NIR/US scan will be performed. Data from the NIR/US scan will be used to validate instrument measurements.

Trial Locations (1)

06032

UConn Health, Farmington

All Listed Sponsors
collaborator

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

NIH

lead

UConn Health

OTHER

NCT02092636 - Ultrasound and Near Infrared Imaging for Breast Cancer Diagnosis and Neoadjuvant Chemotherapy Monitoring | Biotech Hunter | Biotech Hunter